Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ecallantide.

Literature DB >> 20190785

Ecallantide.

Bruce Zuraw, Uma Yasothan, Peter Kirkpatrick.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20190785 DOI： 10.1038/nrd3125

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

5 in total

1. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein.

Authors: A C Ley; W Markland; R C Ladner
Journal: Mol Divers Date: 1996-10 Impact factor: 2.943

2. Plasma bradykinin in angio-oedema.

Authors: J Nussberger; M Cugno; C Amstutz; M Cicardi; A Pellacani; A Agostoni
Journal: Lancet Date: 1998-06-06 Impact factor: 79.321

3. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin.

Authors: W Markland; A C Ley; R C Ladner
Journal: Biochemistry Date: 1996-06-18 Impact factor: 3.162

4. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Authors: Lynda Schneider; William Lumry; Arthur Vegh; Anthony H Williams; Tess Schmalbach
Journal: J Allergy Clin Immunol Date: 2007-06-07 Impact factor: 10.793

5. New treatments addressing the pathophysiology of hereditary angioedema.

Authors: Alvin E Davis
Journal: Clin Mol Allergy Date: 2008-04-14

5 in total

16 in total

1. Plasma kallikrein and diabetic macular edema.

Authors: Edward P Feener
Journal: Curr Diab Rep Date: 2010-08 Impact factor: 4.810

Review 2. Strategies and challenges for the next generation of therapeutic antibodies.

Authors: Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal: Nat Rev Immunol Date: 2010-05 Impact factor: 53.106

Review 3. The new era of C1-esterase inhibitor deficiency therapy.

Authors: Louanne Marie Tourangeau; Bruce L Zuraw
Journal: Curr Allergy Asthma Rep Date: 2011-10 Impact factor: 4.806

Review 4. Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors: Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal: Nat Rev Drug Discov Date: 2015-02-20 Impact factor: 84.694

Review 5. Ecallantide: in acute hereditary angioedema.

Authors: Karly P Garnock-Jones
Journal: Drugs Date: 2010-07-30 Impact factor: 9.546

Review 6. Computational design of protein-ligand interfaces: potential in therapeutic development.

Authors: Andrew Morin; Jens Meiler; Laura S Mizoue
Journal: Trends Biotechnol Date: 2011-02-04 Impact factor: 19.536

7. HAE international home therapy consensus document.

Authors: Hilary J Longhurst; Henriette Farkas; Timothy Craig; Emel Aygören-Pürsün; Claire Bethune; Janne Bjorkander; Konrad Bork; Laurence Bouillet; Henrik Boysen; Anette Bygum; Teresa Caballero; Marco Cicardi; John Dempster; Mark Gompels; Jimmy Gooi; Sofia Grigoriadou; Ursula Huffer; Wolfhart Kreuz; Marcel M Levi; Janet Long; Inmaculada Martinez-Saguer; Michel Raguet; Avner Reshef; Tom Bowen; Bruce Zuraw
Journal: Allergy Asthma Clin Immunol Date: 2010-07-28 Impact factor: 3.406

8. Pyroglutamate and O-linked glycan determine functional production of anti-IL17A and anti-IL22 peptide-antibody bispecific genetic fusions.

Authors: Xiaotian Zhong; Elizabeth Kieras; Eric Sousa; Aaron D'Antona; J Christian Baber; Tao He; Joel Desharnais; Lauren Wood; Deborah Luxenberg; Mark Stahl; Ronald Kriz; Laura Lin; Will Somers; Lori J Fitz; Jill F Wright
Journal: J Biol Chem Date: 2012-11-26 Impact factor: 5.157

9. Ecallantide for the treatment of hereditary angiodema in adults.

Authors: Michael Lunn; Erin Banta
Journal: Clin Med Insights Cardiol Date: 2011-05-17

10. Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism.

Authors: Marc Riedl
Journal: World Allergy Organ J Date: 2010-09 Impact factor: 4.084